Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics | $16.72 | -$7.73 | -31.62% | 409.5K | $2.4B | $10.42$138.81 |
| ICHR | Ichor | $15.91 | -$7.01 | -30.59% | 89.5K | $786.8M | $13.12$36.48 |
| JELD | Jeld-wen | $2.99 | -$1.21 | -28.81% | 162.8K | $358.7M | $2.32$11.66 |
| NOMA | Nomadar | $8.25 | -$3.25 | -28.23% | 48.5K | - | $2.00$57.70 |
| CJET | Chijet Motor | $2.95 | -$0.88 | -22.98% | 189.3K | $350.4M | $2.77$299.00 |
| ARTL | Artelo Biosciences | $2.32 | -$0.68 | -22.52% | 5.8M | $3.4M | $2.30$28.60 |
| FHTX | Foghorn Therapeutics | $3.29 | -$0.92 | -21.85% | 4K | $238.0M | $2.94$9.70 |
| FORD | Forward Industries | $10.96 | -$3.02 | -21.60% | 43.5K | $1.2B | $3.32$46.00 |
| FLYE | Fly-E Group | $7.93 | -$2.07 | -20.73% | 57K | $189.0M | $7.40$166.00 |
| ADTN | Adtran | $8.41 | -$2.02 | -19.37% | 166.7K | $834.9M | $6.02$12.44 |
Related Articles
Featured Article
Is Norwegian Cruise Line Holdings Stock a Buy After Earnings?
Will Healy|Aug 6, 2025
Norwegian appears set to sail smoothly even after voicing concerns in its previous report.
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Cory Renauer|Dec 15, 2024
Best Stock to Buy Right Now: Carnival Corporation vs. Norwegian Cruise Line
Collin Brantmeyer|Sep 3, 2024
These cruise operators are still reeling from the pandemic, but hope may be on the horizon.
This Institutional Investor Just Increased Its Stake in Norwegian Cruise Lines by Nearly 10%. Should You Do the Same?
Will Healy|Jul 21, 2024
The decision of whether to follow GSA Capital's lead may lie in the manager's investing approach.
If You'd Invested $1,000 in Norwegian Cruise Line Stock 5 Years Ago, Here's How Much You'd Have Today
David Moadel|Jul 13, 2024
Compared to pre-pandemic prices, Norwegian Cruise Line stock still has a lot of catching up to do.
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Alex Carchidi|Jul 6, 2024
One key issue remains unresolved, and it could be a significant one.
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
David Jagielski|Jul 4, 2024
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.
1 Soaring Growth Stock to Buy and Hold for 10 Years
Prosper Junior Bakiny|Jul 3, 2024
Let's look beyond the biotech's performance this year.
Should You Buy Norwegian Cruise Line Stock Down 20% From Its 52-Week High?
Joseph Arroyo|Jun 27, 2024
A 20% decline may not be enough to justify the risks of owning Norwegian.
